TNXP 8k: Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD http://www.tonixpharma.com/news-events/press-releases/detail/1069/tonix-pharmaceuticals-presented-analyses-of-potential